LEGN supply chain intelligence for Legend Biotech Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Legend Biotech Corporation (LEGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GENSCRIPT | GENSCRIPT | 90% | We rely on Genscript to provide certain services. |
| HEMACARE | HEMACARE | 85% | we purchase equipment and reagents critical for the manufacture of our product candidates from Hemacare, Miltenyi, Leukapheresis Collection Center and other suppliers on a purchase order basis. |
| LEUKAPHERESIS-COLLECTION-CENTER | LEUKAPHERESIS-COLLECTION-CENTER | 85% | we purchase equipment and reagents critical for the manufacture of our product candidates from Hemacare, Miltenyi, Leukapheresis Collection Center and other suppliers on a purchase order basis. |
| MILTENYI | MILTENYI | 85% | we purchase equipment and reagents critical for the manufacture of our product candidates from Hemacare, Miltenyi, Leukapheresis Collection Center and other suppliers on a purchase order basis. |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO g… |
| ALLO | Allogene Therapeutics, Inc. | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| AUTL | Autolus Therapeutics plc | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| AUTL | Autolus Therapeutics plc | 72% | Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: ct and product candidates have a li… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: ct and product candidates have a … |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish an… |
| CRBU | Caribou Biosciences, Inc. | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of th… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from GSK graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from GSK grap… |
| JNJ | Johnson & Johnson | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and… |
| NVSEF | Novartis AG | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish a… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish an… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO g… |
| AUTL | Autolus Therapeutics plc | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| AUTL | Autolus Therapeutics plc | 72% | Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comp… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from LEGN graph: es, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict … |
| BMY | Bristol-Myers Squibb Company | 72% | es, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise fro… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • com… |
| BMYMP | Bristol-Myers Squibb Co | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| CRBU | Caribou Biosciences, Inc. | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from CRBU g… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely… |
| GSK | GSK plc | 72% | y be observed in other studies; • obtain adequate and timely supply of CARVYKTI, which may in the future be adversely affected by factors relating to our manufacturing capabilities, global pandemics,… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from GSK graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from GSK grap… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of … |
| JNJ | Johnson & Johnson | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| NVSEF | Novartis AG | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSE… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure o… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta… |
| TCRX | TScan Therapeutics, Inc. | 72% | Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel… |
| BAC | Bank of America Corporation | 62% | Reciprocal relationship from BAC graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BAC graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BAC grap… |
| NVS | Novartis AG | 62% | Reciprocal relationship from NVS graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVS graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVS grap… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LEGN-DEBT | Debt stack $389.3M | 90% | Market cache reports total debt of $389.3M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LEGN-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 195 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 1 | ['customer', 'supplier'] |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DEO | Diageo plc | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 |